Cargando…
Impact of Pathologic Complete Response following Neoadjuvant Chemotherapy ± Trastuzumab in Locally Advanced Breast Cancer
PURPOSE: This study was designed to examine the relationship between breast cancer molecular subtypes and pathological response to neoadjuvant chemotherapy (NAC) ± trastuzumab, in locally advanced breast cancer (LABC). METHODS: Female patients with LABC (T2–T4, N0–N2, and M0) who received neoadjuvan...
Autores principales: | Al-Tweigeri, Taher, Elshenawy, Mahmoud, Badran, Ahmed, Omar, Ayman, Suleman, Kausar, Al Malik, Osama, Anwar, Ihab, Jastaniya, Noha, Tulbah, Asma, Al Shabanah, Mohammad, Ajarim, Dahish, Al Sayed, Adher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7895557/ https://www.ncbi.nlm.nih.gov/pubmed/33628241 http://dx.doi.org/10.1155/2021/6639763 |
Ejemplares similares
-
Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer
por: Ghebeh, Hazem, et al.
Publicado: (2021) -
Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer
por: Alshamsan, Bader, et al.
Publicado: (2021) -
Single-Institute Review of HER-2/Neu-Positive Invasive Lobular Breast Carcinoma in an Arab Population
por: Osmani, Asif Husain, et al.
Publicado: (2021) -
Being 40 or younger is an independent risk factor for relapse in operable breast cancer patients: The Saudi Arabia experience
por: Elkum, Naser, et al.
Publicado: (2007) -
Complete Response of Chemo-Refractory Metastatic Metaplastic Breast Cancer to Paclitaxel-Immunotherapy Combination
por: Al Sayed, Adher D., et al.
Publicado: (2019)